Benjamin Trevino
Medical · Weslaco, TXNPI 1982021408
Payments from drug & device makers
Across 150 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$641
- Novo Nordisk$636
- AbbVie$546
- AstraZeneca$395
- GSK$332
- Johnson & Johnson$302
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,02698%
- Education$922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $641 |
| Novo Nordisk | 29 | $636 |
| AbbVie | 12 | $546 |
| AstraZeneca(2 entities) | 15 | $395 |
| GSK | 11 | $332 |
| Johnson & Johnson | 5 | $302 |
| Amgen | 9 | $227 |
| Ultragenyx Pharmaceutical Inc. | 2 | $201 |
| Bayer | 6 | $143 |
| Abbott | 6 | $117 |
| Astellas Pharma US Inc | 2 | $100 |
| Exact Sciences | 5 | $85 |
| Dexcom, Inc. | 4 | $82 |
| Genentech USA, Inc. | 1 | $62 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Phadia US Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Pfizer | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,118 in reported general payments places this provider in the 80th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 24 | $30,984 |
| OzempicSemaglutide | 23 | $30,066 |
| MounjaroTirzepatide | 15 | $23,271 |
| EliquisApixaban | 19 | $18,999 |
| RybelsusSemaglutide | 11 | $16,822 |
| FarxigaDapagliflozin Propanediol | 15 | $16,704 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $9,137 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,932 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $5,323 |
| PaxlovidNirmatrelvir/Ritonavir | 11 | $1,359 |
| Gabapentin | 48 | $946 |
| Esomeprazole Magnesium | 11 | $764 |
| Metoprolol Succinate | 52 | $689 |
| Rosuvastatin Calcium | 61 | $559 |
| Omeprazole | 21 | $478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $636 | $46,88834 claims |
| Boehringer IngelheimJardiance | $18 | $30,98424 claims |
| Lilly USA, LLCMounjaro | $641 | $23,27115 claims |
| PfizerEliquis, Paxlovid | $16 | $20,35830 claims |
| AstraZenecaFarxiga | $395 | $16,70415 claims |
| GSKTrelegy Ellipta | $332 | $7,93211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,490 medical providers in Texas.
Other medical in Weslaco
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.